Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice

Molecular Therapy

Volumn 22, Issue 4, 2014, Pages 702-712

  Elmallah, Mai K ^a   Falk, Darin J ^a,b   Nayak, Sushrusha ^a,b   Federico, Roland A ^b   Sandhu, Milapjit S ^b   Poirier, Amy ^a   Byrne, Barry J ^a,b   Fuller, David D ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAN 1,4 ALPHA GLUCOSIDASE; GLYCOGEN; PARVOVIRUS VECTOR; ALPHA GLUCOSIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FEMALE; GENE ACTIVITY; GENE EXPRESSION; GLYCOGEN STORAGE DISEASE TYPE 2; HISTOPATHOLOGY; IMMUNE RESPONSE; INTRALINGUAL INJECTION; INTRAMUSCULAR DRUG ADMINISTRATION; LUNG VENTILATION; MALE; MOTONEURON; MOUSE; MUSCLE FIBRIL; NONHUMAN; SEROTYPE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENOME; WEIGHT GAIN; ANIMAL; BIOSYNTHESIS; DEPENDOPARVOVIRUS; GENE EXPRESSION REGULATION; GENE THERAPY; GENE TRANSFER; GENETICS; GLYCOGEN STORAGE DISEASE TYPE II; HUMAN; METABOLISM; PATHOLOGY; PROMOTER REGION; SKELETAL MUSCLE;

ADENO-ASSOCIATED VIRUS; ANIMALIA; MUS;

ALPHA-GLUCOSIDASES; ANIMALS; DEPENDOVIRUS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GLYCOGEN; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; INJECTIONS, INTRAMUSCULAR; MICE; MOTOR NEURONS; MUSCLE, SKELETAL; MYOFIBRILS; PROMOTER REGIONS, GENETIC;

EID: 84897573702     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.282     Document Type: Article

References (50)

1. Fuller DD, ElMallah MK, Smith BK, Corti M, Falk DJ, Byrne BJ. Pompe disease and the respiratory system. Res Physiol Neurobiol 2013;189:241-249
2. Byrne BJ, Falk DJ, Pacak CA, et al. Pompe disease gene therapy. Hum Mol Genet 2011;20(R1):R61-8
3. Jones HN, Muller CW, Lin M, et al. Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia 2010;25:277-83
4. Margolis ML, Howlett P, Goldberg R, Eftychiadis A, Levine S. Obstructive sleep apnea syndrome in acid maltase deficiency. Chest 1994;105:947-9
5. Muller CW, Jones HN, OGrady G, Suarez AH, Heller JH, Kishnani PS. Language and speech function in children with infantile Pompe disease. J Ped Neurol 2009;7:147-156
6. Mah C, Pacak CA, Cresawn KO, et al. Physiological correction of Pompe disease by systemic delivery of adeno-Associated virus serotype 1 vectors. Mol Ther 2007;15:501-7
7. Mah CS, Falk DJ, Germain SA, et al. Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther 2010;18:502-10
8. DeRuisseau LR, Fuller DD, Qiu K, et al. Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci U S A 2009;106:9419-24
9. Towne C, Schneider BL, Kieran D, Redmond DE Jr, Aebischer P. Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther 2010;17:141-6
10. Kaspar BK, Lladó J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301:839-42
11. ElMallah MK, Falk DJ, Lane MA, et al. Retrograde gene delivery to hypoglossal motoneurons using adeno-Associated virus serotype 9. Hum Gene Ther Methods 2012;23:148-56
12. Raben N, Nagaraju K, Lee E, et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem 1998;273:19086-92
13. Dubrovsky A, Corderi J, Lin M, Kishnani PS, Jones HN. Expanding the phenotype of late-onset Pompe disease: Tongue weakness: A new clinical observation. Muscle Nerve 2011;44:897-901
14. Hobson-Webb LD, Jones HN, Kishnani PS. Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement. Neuromuscul Disord 2013;23:319-23
15. Chien YH, Lee NC, Thurberg BL, et al. Pompe disease in infants: Improving the prognosis by newborn screening and early treatment. Pediatrics 2009;124:e1116-25
16. Smith BK, Collins S, Conlon T, Mah C, Lawson LA, Martin D, et al. Phase I/II trial of AAV1-GAA gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: Initial safety and ventilatory outcomes. Hum Gene Ther 2013
17. Benkhelifa-Ziyyat S, Besse A, Roda M, et al. Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther 2013;21:282-90
18. Lee KZ, Qiu K, Sandhu MS, et al. Hypoglossal neuropathology and respiratory activity in pompe mice. Front Physiol 2011;2:31
19. Lomask M. Further exploration of the Penh parameter. Exp Toxicol Pathol 2006;57(suppl 2):13-20
20. van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-40
21. Sidman RL, Taksir T, Fidler J, et al. Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice. J Neuropathol Exp Neurol 2008;67:803-18
22. Bostick B, Ghosh A, Yue Y, Long C, Duan D. Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther 2007;14:1605-9
23. Raben N, Danon M, Gilbert AL, et al. Enzyme replacement therapy in the mouse model of Pompe disease. Mol Genet Metab 2003;80:159-69
24. Towne C, Raoul C, Schneider BL, Aebischer P. Systemic AAV6 delivery mediating RNA interference against SOD1: Neuromuscular transduction does not alter disease progression in fALS mice. Mol Ther 2008;16:1018-25
25. Gransee HM, Zhan WZ, Sieck GC, Mantilla CB. Targeted delivery of TrkB receptor to phrenic motoneurons enhances functional recovery of rhythmic phrenic activity after cervical spinal hemisection. PLoS One 2013;8:e64755
26. Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol 2009;27:59-65
27. Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust K, Bringas J, et al. AAV9 transduction in the central nervous system of non-human primates. Hum Gene Ther 2012;23:382-389
28. Bevan AK, Duque S, Foust KD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther 2011;19:1971-80
29. Samaranch L, Salegio EA, San Sebastian W, et al. Adeno-Associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther 2012;23:382-9
30. Manfredsson FP, Rising AC, Mandel RJ. AAV9: A potential blood-brain barrier buster. Mol Ther 2009;17:403-5
31. Mah C, Cresawn KO, Fraites TJ Jr, et al. Sustained correction of glycogen storage disease type II using adeno-Associated virus serotype 1 vectors. Gene Ther 2005;12:1405-9
32. Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of pre-And posttreatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 2006;86:1208-20
33. Kikuchi T, Yang HW, Pennybacker M, et al. Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 1998;101:827-33
34. Teng YT, Su WJ, Hou JW, Huang SF. Infantile-onset glycogen storage disease type II (Pompe disease): Report of a case with genetic diagnosis and pathological findings. Chang Gung Med J 2004;27:379-84
35. Willemsen MA, Jira PE, Gabreëls FJ, van der Ploeg AT, Smeitink JA. Three hypotonic neonates with hypertrophic cardiomyopathy: Pompe's disease. Ned Tijdschr Geneeskd 1998;142:1388-92
36. Gambetti P, DiMauro S, Baker L. Nervous system in Pompe's disease. Ultrastructure and biochemistry. J Neuropathol Exp Neurol 1971;30:412-30
37. Bellettato CM, Scarpa M. Pathophysiology of neuropathic lysosomal storage disorders. J Inherit Metab Dis 2010;33:347-62
38. Fuller DD, ElMallah MK, Smith BK, et al. The respiratory neuromuscular system in Pompe disease. Respir Physiol Neurobiol 2013;189:241-9
39. Hartung SD, Reddy RG, Whitley CB, McIvor RS. Enzymatic correction and cross-correction of mucopolysaccharidosis type I fibroblasts by adeno-Associated virus-mediated transduction of the alpha-L-iduronidase gene. Hum Gene Ther 1999;10:2163-72
40. Skorupa AF, Fisher KJ, Wilson JM, Parente MK, Wolfe JH. Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp Neurol 1999;160:17-27
41. Reimsnider S, Manfredsson FP, Muzyczka N, Mandel RJ. Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 2007;15:1504-11
42. Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE. Treatment of infantile Pompe disease with alglucosidase alpha: The UK experience. J Inherit Metab Dis 2010;33:747-50
43. van Gelder CM, van Capelle CI, Ebbink BJ, et al. Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis 2012;35:505-11
44. Rohrbach M, Klein A, Köhli-Wiesner A, et al. CRIM-negative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 2010;33:751-7
45. Lu YY, Wang LJ, Muramatsu S, et al. Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport. Neurosci Res 2003;45:33-40
46. Mitzner W, Tankersley C. Interpreting Penh in mice. J Appl Physiol (1985) 2003;94:828-31; author reply 831-2
47. Jones HN, Muller CW, Lin M, et al. Oropharyngeal dysphagia in infants and children with infantile Pompe disease. Dysphagia 2010;25:277-83
48. Zolotukhin S, Potter M, Zolotukhin I, et al. Production and purification of serotype 1, 2, and 5 recombinant adeno-Associated viral vectors. Methods 2002;28:158-67
49. Obernier JA, Baldwin RL. Establishing an appropriate period of acclimatization following transportation of laboratory animals. ILAR J 2006;47:364-9
50. Elder ME, Nayak S, Collins SW, et al. B-Cell depletion and immunomodulation before initiation of enzyme replacement therapy blocks the immune response to acid alphaglucosidase in infantile-onset Pompe disease. J Pediatr 2013;163:847-54.e1.